（文章来源：证券日报） 证券日报网讯 1月9日，爱美客在互动平台回答投资者提问时表示，公司注射用A型肉毒毒素在韩国市场 已积累多年临床应用数据，其临床安全与稳定性得到了市场的验证，该产品通过与公司现有产品的组 合，能为客户提供更全面的综合解决方案，有利于增强公司的核心竞争力。 ...

Group 1 - The medical beauty sector increased by 2.39% on January 9, with Ai Meike leading the gains [1] - The Shanghai Composite Index closed at 4120.43, up 0.92%, while the Shenzhen Component Index closed at 14120.15, up 1.15% [1] - Key stocks in the medical beauty sector showed varied performance, with Ai Meike closing at 149.91, up 2.69%, and *ST Meigu closing at 3.34, down 1.18% [1] Group 2 - The medical beauty sector saw a net inflow of 192.35 million yuan from main funds, while retail investors experienced a net outflow of 3038.42 million yuan [1] - Specific stock fund flows indicated that Huaxi Biological had a main fund net inflow of 11.58 million yuan, while Ai Meike had a net outflow of 3941.60 million yuan from retail investors [2] - *ST Meigu had a significant net outflow of 1095.28 million yuan from main funds, but a net inflow of 956.07 million yuan from retail investors [2]

Investment Rating - The report gives a "Market Perform" rating for the pharmaceutical and biotechnology industry, indicating that the industry index is expected to perform within ±10% of the market index over the next six months [26][32]. Core Insights - The SW pharmaceutical and biotechnology industry outperformed the CSI 300 index, rising by 3.61% from December 26, 2025, to January 8, 2026, exceeding the CSI 300 index by approximately 1.56 percentage points [12]. - Most sub-sectors within the industry recorded positive returns during the same period, with the hospital and medical R&D outsourcing sectors leading with increases of 10.62% and 7.39%, respectively [13]. - Approximately 82% of stocks in the industry achieved positive returns, with notable performers including Xiangyu Medical, which saw a weekly increase of 57.50% [14][17]. - The overall industry valuation has risen, with the SW pharmaceutical and biotechnology index's PE (TTM) at approximately 52.75 times, which is 3.78 times higher than the CSI 300 index [18][26]. Summary by Sections 1. Market Review - The SW pharmaceutical and biotechnology industry outperformed the CSI 300 index, with a rise of 3.61% from December 26, 2025, to January 8, 2026 [12]. - Most sub-sectors recorded positive returns, particularly hospitals and medical R&D outsourcing, which increased by 10.62% and 7.39%, respectively [13]. - About 82% of stocks in the industry had positive returns, with significant gains from several companies [14]. 2. Industry News - The report highlights the acceleration of volume-based procurement in 2026, with various local and national initiatives underway to streamline drug procurement processes [24]. - A new batch of encouraged generic drugs has been announced, focusing on optimizing the drug supply system and enhancing the availability of essential medications [23]. 3. Company Announcements - Jiangsu Yahui Pharmaceutical announced the completion of the first patient enrollment in a Phase I clinical trial for its drug APL-2401, targeting advanced solid tumors [25]. 4. Industry Outlook - The report suggests a focus on investment opportunities in the brain-computer interface sector, particularly following announcements from Neuralink regarding large-scale production plans [26]. - Recommended stocks for attention include leading companies in medical devices, pharmaceutical retail, aesthetic medicine, and innovative drugs, among others [28][29].

Core Viewpoint - The company has received approval from the National Medical Products Administration for its exclusive distribution of injectable type A botulinum toxin produced by Huons BioPharma Co., Ltd, marking a significant milestone in its strategic layout [1] Group 1 - The approval of the injectable type A botulinum toxin product is a key milestone in the company's strategic planning [1] - The product will enhance the company's core competitiveness by providing a more comprehensive solution to customers when combined with existing products [1]

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Views - The company has successfully obtained approval for its injectable type A botulinum toxin product, which is expected to drive revenue growth due to its established distribution channels and brand strength [5] - The domestic market for botulinum toxin is anticipated to have significant growth potential, as the demand is currently lower than that for hyaluronic acid, with projections indicating a compound annual growth rate (CAGR) of 27.6% from 2026 to 2030 [6] - The approval process for botulinum toxin products is stringent, which is expected to maintain a favorable competitive landscape for the company [7] - The company is projected to achieve net profits of 1.39 billion, 1.53 billion, and 1.70 billion yuan for the years 2025 to 2027, respectively, with corresponding earnings per share (EPS) of 4.58, 5.06, and 5.63 yuan [7] Financial Performance - The company’s revenue is forecasted to reach 2.43 billion yuan in 2025, with a significant decline of 19.81% compared to the previous year, followed by a recovery in subsequent years [9] - The net profit for 2025 is estimated at 1.39 billion yuan, reflecting a decrease of 29.15% from 2024 [9] - The company’s gross margin is expected to remain high, around 93.9% in 2025, indicating strong profitability [11] Market Position - The company holds a 25.4% stake in Huons BP, ensuring stable product supply and enhancing its competitive position in the market [5] - The report highlights the company as a leading player in the aesthetic medicine sector, benefiting from significant research and technological advantages [7]

Group 1 - Wanhua Chemical's Yantai Industrial Park's ethylene unit has completed a technical upgrade and resumed production, achieving flexible feedstock switching between ethane and propane, enhancing competitiveness in the petrochemical industry [1] - United Water has won a long-term operation contract for municipal wastewater treatment in Saudi Arabia, with an estimated total investment of approximately 378 million RMB over a 15-year cooperation period [2] - Minsheng Health plans to invest 98 million RMB to establish a fund focused on the health industry, contributing 49% of the total fund size of 200 million RMB [3] Group 2 - Jialitu's shareholder, Anle Group, plans to reduce its stake by up to 3% of the company's total shares [4] - Laiyifen's controlling shareholder intends to reduce its stake by no more than 3% of the total shares [5] - Taifu Pump's actual controller's concerted action party plans to reduce its stake by up to 0.535% [7] Group 3 - Vanke A's executive vice president, Yu Liang, has resigned due to retirement [8] - Tian Sheng New Materials has suspended trading due to a potential change in control involving its largest shareholder [10] - Taisun Wind Power is in the early stages of business layout in the commercial aerospace sector [11] Group 4 - Lushin Investment holds only 0.89% equity in Blue Arrow Aerospace, indicating minimal impact on its financial status [12] - Huibo Pu's controlling shareholder is planning a change in control, leading to stock suspension [13] - Tubaobao's subsidiary is selling a stake in Daziran Home and acquiring specific equity for 4 billion RMB [14] Group 5 - Xingchen Technology plans to repurchase shares worth between 60 million and 120 million RMB for employee stock ownership plans [15] - Pulite expects no large-scale orders for its LCP film products in the brain-computer interface sector in the short term [16] - Rijiu Optoelectronics plans to raise up to 800 million RMB through a private placement for a functional film project [17] Group 6 - Yingqu Technology forecasts a net profit increase of 114.69% to 162.4% in 2025, with expected revenue growth of 13% to 18% [19] - Shanda Electric has won a project from Southern Power Grid worth approximately 13.43 million RMB [20] - Changhong Technology's subsidiary has secured over half of a major semiconductor customer's procurement share, amounting to over 10 million RMB [21] Group 7 - Pairui Co. has signed a framework agreement for bulk procurement of IGBT chips, with projected orders totaling approximately 1.74 billion RMB [22] - Aimeike has received a drug registration certificate for its exclusive distribution of injectable botulinum toxin products in China [23] - Quanyin High-Tech's stock will resume trading after a takeover offer from Zhongzhong Group, which now holds 40.51% of the company [24] Group 8 - Hailiang Co. has decided to suspend its investment in Jinlong Group due to significant external changes [25] - Quanxin Co. plans to issue convertible bonds to raise up to 312 million RMB for aviation communication projects [26] - Kangtai Bio's clinical trial application for a combined vaccine has been accepted by the National Medical Products Administration [27] Group 9 - Huaxia Happiness expects to report a net loss for 2025, with losses projected to exceed the previous year's audited net assets [28] - Xianju Pharmaceutical has received a drug registration certificate for Betamethasone Sodium Phosphate Injection [29] - Huaxia Happiness's controlling shareholder is involved in arbitration with a claim amount of approximately 6.4 billion RMB [30] Group 10 - Shaoneng Co. has launched its smart control center project, with an investment of 8.7 million RMB [31] - Jiangshun Technology is planning to establish an investment fund with professional institutions, with details still under discussion [32] - Beifang Changlong intends to acquire 51% of Shunyi Technology, which may constitute a major asset restructuring [33] Group 11 - Guoji Heavy Industry's revenue from "controlled nuclear fusion" products is currently negligible [34] - Hongrun Construction's shareholder plans to reduce its stake by up to 0.12% [35] - Puni Testing expects a net loss of 200 to 250 million RMB for 2025, although this represents an improvement from the previous year's loss [36] Group 12 - Kede Education's controlling shareholder is planning a change in control through a share transfer agreement [38] - Zhongwei Company’s major shareholder plans to reduce its stake by up to 2% [39] - Tongcheng New Materials is planning to issue H-shares and apply for listing on the Hong Kong Stock Exchange [40] Group 13 - ST Jianyi's shareholder plans to reduce its stake by up to 1.23% [41]

Core Viewpoint - Elon Musk's Neuralink plans to start mass production of brain-machine interfaces by 2026, marking a significant step towards the commercialization of this technology [2] Industry Developments - The brain-machine interface sector in China is accelerating, with the country becoming the second to enter clinical trials for invasive brain-machine interfaces after the United States [2] - In 2025, there were 24 financing events in the domestic brain-machine interface field, a 30% year-on-year increase [3] - Hubei Province has set a price for invasive brain-machine interface medical services at approximately 6,552 yuan, indicating a move towards making this technology more accessible [3] Technology and Market Segmentation - Brain-machine interfaces serve as a bridge between the brain and external devices, with three main technological approaches: invasive, non-invasive, and semi-invasive [4][5] - The largest market segment for brain-machine interfaces is currently in healthcare, accounting for over 56% of applications, particularly for neurological diseases like epilepsy and Parkinson's [6] - McKinsey predicts that the global market for medical applications of brain-machine interfaces could reach $40 billion by 2030 and $145 billion by 2040 [6] Investment Opportunities - While the brain-machine interface sector shows promise, most companies are still far from profitability, with significant time needed for medical applications to gain approval [7] - Instead of focusing on individual companies, it may be more prudent to consider the broader medical device industry, particularly through medical device ETFs that encompass leading firms in this space [8]

Investment & Operations - Aimeike's exclusive distribution of botulinum toxin type A injection product has received drug registration certificate [1] - Kangtai Biological's clinical trial application for acellular pertussis-diphtheria-tetanus (component) combined vaccine has been accepted [1] - Runjian Co. signed a strategic cooperation framework agreement with JD Technology to expand in AI applications and intelligent computing cloud [1] - Zhongwu Drone signed a contract for drone systems worth over 100 million, expected to positively impact annual operating performance [1] - Jiechuang Intelligent plans to procure IT equipment and spare parts totaling no more than 4 billion for cloud computing business [1] - Pairui Co. signed a bulk procurement framework agreement for IGBT chips, with forecasted supply total amounting to approximately 131.4 billion for 2028, 2029, and 2030 [1] - Poly United won a bid for a 1.528 billion yuan stripping engineering project [1] - Quanxin Co. plans to issue convertible bonds to raise no more than 312 million for commercial aviation transmission and integrated communication products [1] - Guangdong Power A's Huizhou power plant expansion project (2×1000MW) has commenced operation for unit 5, with a total investment of 8.05 billion [1] - Changhong Technology's subsidiary has secured semiconductor consumables orders from a major domestic wafer factory, expected to account for over half of procurement share by 2026 [1] Performance - Jinli Permanent Magnet expects a net profit increase of 127%-161% year-on-year for 2025, with small batch deliveries of embodied robot motor rotors and magnetic materials [1] - Yingqu Technology anticipates a net profit increase of 114.69%-162.40% year-on-year for 2025 [1] - Absen expects a net profit increase of 105.32%-148.09% year-on-year for 2025 [1] - Industrial Fulian plans to distribute cash dividends totaling 6.55 billion (including tax) for the first half of 2025, with the equity registration date set for January 15, 2026 [1] Capital Operations - Beifang Changlong plans to acquire 51% of Shunyi Technology, expected to constitute a major asset restructuring [2] - Huibo Pu is planning to transfer 25%-30% of its shares, leading to stock suspension [2] - Tiansheng New Materials' largest shareholder Wu Haizhou is planning significant matters that may lead to a change in control, resulting in stock suspension [2] - Quanyin High-Tech's offer from Zhongzhong Group has expired, and the stock will resume trading [2] - Kede Education's actual controller plans to transfer 23.57% of its shares, with Huaxin Future becoming the controlling shareholder [2]

Market Overview - On January 8, the Shanghai Composite Index fell by 0.07%, the Shenzhen Component Index decreased by 0.51%, and the ChiNext Index dropped by 0.82%. The total trading volume in the Shanghai and Shenzhen markets was 2.8 trillion yuan, a decrease of 53.8 billion yuan compared to the previous trading day, marking the fourth consecutive day of trading volume exceeding 2.5 trillion yuan. Over 3,700 stocks rose, with 111 stocks hitting the daily limit. Key sectors showing strength included commercial aerospace, brain-computer interface, controllable nuclear fusion, and AI applications, while large financials, rare earth permanent magnets, and non-ferrous metals saw significant declines [1][2]. International Market - In the U.S. stock market on January 8, the Dow Jones Industrial Average rose by 270.03 points to close at 49,266.11, a gain of 0.55%. The S&P 500 increased by 0.53 points to 6,921.46, a rise of 0.01%, while the Nasdaq Composite fell by 104.26 points to 23,480.02, a decline of 0.44%. In Europe, the FTSE 100 closed at 10,044.69, down 3.52 points (0.04%), while the CAC 40 rose by 9.55 points (0.12%) to 8,243.47, and the DAX increased by 5.20 points (0.02%) to 25,127.46 [2]. Oil Market - International oil prices rose on January 8, with light crude oil futures for February delivery increasing by $1.77 to $57.76 per barrel, a rise of 3.16%. Brent crude oil for March delivery rose by $2.03 to $61.99 per barrel, a gain of 3.39% [3]. Corporate Developments - The Ministry of Commerce of China responded to the review of Meta's acquisition of the AI platform Manus, stating that enterprises must comply with Chinese laws and regulations when engaging in foreign investment and technology cooperation [4]. - China Petroleum & Chemical Corporation (Sinopec) and China Aviation Oil Holding Company announced a restructuring, which is expected to enhance the competitiveness of China's aviation fuel industry and support the green transformation of the aviation sector [5]. - Guangzhou's new plan aims to accelerate the development of strategic industries, including low-altitude economy and aerospace, with a focus on reusable rocket technology [6]. - Zhiyuan Technology is set to launch a new generation of foundational model GLM-5, with expectations of significant growth in the large language model market in the coming years [7]. - OpenAI introduced ChatGPT Health, targeting the rapidly growing AI healthcare market, which is projected to reach approximately $505.59 billion by 2033 [8]. Regulatory Actions - The State Administration for Market Regulation of China has conducted talks with six leading photovoltaic companies regarding anti-monopoly risks, emphasizing the need for compliance with regulations on production capacity and pricing [9]. - The Ministry of Industry and Information Technology has warned against irrational competition in the lithium battery industry, gathering major players to discuss regulatory measures [10][11]. Investment Insights - Xiangcai Securities suggests that long-term industrial upgrades in China may create a favorable policy environment for market stability, particularly benefiting sectors like insurance, agriculture, aerospace, and technology [12]. - Galaxy Securities highlights the investment opportunities in the "AI + manufacturing" sector, focusing on the entire value chain from upstream to downstream applications [12].

Group 1: Regulatory Responses - The Ministry of Commerce stated that companies engaging in foreign investment and related activities must comply with Chinese laws and regulations, particularly regarding Meta's acquisition of Manus [1] - The State Administration for Market Regulation has conducted discussions with six leading photovoltaic companies and the industry association, emphasizing the prohibition of collusion on production capacity and pricing [2] Group 2: Industry Developments - Guangzhou is accelerating the construction of liquid rocket assembly and testing bases, focusing on reusable rocket technology to enhance national aerospace capabilities [3] - China Petroleum and Chemical Corporation and China Aviation Oil Group have initiated a restructuring process approved by the State Council [4] Group 3: Banking Sector Adjustments - Several small and medium-sized banks have announced adjustments to deposit interest rates, with most continuing a trend of rate cuts while some have selectively increased rates [5] Group 4: Market Trends - The U.S. stock market showed mixed results, with the Dow Jones Industrial Average rising by 270.03 points, while the Nasdaq Composite fell by 104.26 points [6] - The Chinese concept stocks listed in the U.S. saw a general increase, with the Nasdaq Golden Dragon China Index rising by 1.09% [7] Group 5: Commodity Market Movements - The U.S. dollar index increased by 0.24%, while gold prices rose by 0.37% to $4473.13 per ounce [9] - Crude oil futures increased by $1.77, marking a 3.16% rise to $57.76 per barrel [9] Group 6: Industry Meetings - A meeting was held by the Ministry of Industry and Information Technology and other departments to address the rapid development of the power and energy storage battery industry, highlighting issues of irrational competition and the need for regulatory governance [12]